Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GJB2 | P29033 | 4/20 | 0.42 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.41 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.41 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.41 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | FGF1 | P05230 | 3/20 | 0.32 |
| ▸ | FGF2 | P09038 | 3/20 | 0.32 |
| ▸ | VEGFA | P15692 | 3/20 | 0.32 |
| ▸ | HPSE | Q9Y251 | 3/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15481866 | 1.00 | GJB2 (0.42) | GJB2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL16576214 | 1.00 | GJB2 (0.42) | GJB2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL10154158 | 1.00 | GJB2 (0.42) | GJB2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL14440635 | 0.94 | SSTR1 (0.45) | GJB2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL10240796 | 0.93 | SSTR1 (0.43) | GJB2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL14302433 | 0.87 | TNF (0.43) | GJB2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL14310974 | 0.87 | TNF (0.43) | GJB2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL10600403 | 0.87 | GJB2 (0.43) | GJB2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL10600399 | 0.87 | GJB2 (0.43) | GJB2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL15003969 | 0.86 | SSTR1 (0.52) | GJB2SSTR1SSTR2SSTR4SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2016-08-04 | — | — | US | disclosed |
| WO-2015038596-A1 | NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2015-03-19 | — | — | WO | disclosed |
| WO-2014124430-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2014-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, NTPCR, TYMP | GJB2 1247/4885SSTR1 4845/4885SSTR2 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.